SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending after a significant drop following mixed Phase 3 trial results, specifically related to high placebo response impacting statistical significance. The conversation centers on whether the sell-off is an overreaction given the company's cash reserves and ongoing pipeline, with some speculating about a potential buyout and others wary of the mixed data. Community members are actively discussing dip-buying strategies, potential bounce-back scenarios, and comparisons to competitor performance.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Shares of Robinhood are trending as the stock rallies to new all-time highs, fueled by optimism around its S&P 500 inclusion and growth in its prediction markets business; the community is closely watching for continued momentum. Several analysts have recently raised their price targets, with some traders speculating on further upside. The stock has become a favorite among millennial traders as it rides the crypto wave and wealth transfer megatrend.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

AUPH is trending due to a sharp drop in stock price following remarks made by a former FDA official, George Tidmarsh, regarding the drug Voclosporin. The community is expressing concerns about the validity and timing of the statement, with some suspecting market manipulation and questioning the company's leadership response. The drop has also impacted buyout hopes.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is trending following news of a partnership with Google to enhance AI-powered shopping experiences. While some investors are excited about the potential growth, others express frustration with the stock's historical underperformance and question whether the partnership will provide an immediate catalyst. Community members are debating whether this is a turning point or another false start for the fintech giant.

Advisorshares Trust - AdvisorShares Pure US Cannabis ETF

AdvisorShares Pure US Cannabis ETF

MSOS is trending as cannabis stocks react to a video posted by Trump discussing the medical benefits of CBD for seniors, sparking community discussion around potential rescheduling.  Traders are actively weighing the implications of potential policy changes and the sector's volatile nature, while some highlight positive movement in European cannabis markets. The community speculates on the timing and impact of any official announcements.

Boqii Holding Ltd. operates as a holding company with interest in operating online pet stores. It provides services through its subsidiaries. The company was founded by Liang Hao, Tang Yingzhi, and Chen Di in December 2007 and is headquartered in Shanghai, China.

Boqii Holding Limited - Ordinary Shares - Class A

Boqii Holding Limited - ADR

Boqii Holding is trending due to speculation around a potential gamma squeeze and significant price movement, leading to community discussions about float size and potential price targets. Some traders are pointing to technical indicators and chart patterns, while others caution about the risks associated with Chinese stocks and potential pump-and-dump schemes. The stock's volatility and history of reverse splits are also prominent points of discussion among investors.

Shopify, Inc. is a global commerce company that provides essential internet infrastructure for commerce, offering trusted tools to start, scale, market, and run a retail business of any size. The Company's software enables merchants to run their business across all of their sales channels, including web and mobile storefronts, physical retail locations, social media storefronts and marketplaces. The Shopify platform provides merchants with a single view of their business across all of their sales channels and enables them to manage products and inventory, process orders and payments, fulfill and ship orders, build customer relationships, source products, leverage analytics and reporting and access financing, all from one integrated back office. The company was founded on September 28, 2004 and is headquartered in Ottawa, Canada.

Shopify Inc - Ordinary Shares - Class A (Sub Voting)

Shopify Inc

Shopify is trending following a strong earnings report, with revenue and GMV growth exceeding expectations. The community is discussing the company's resilience in the face of potential headwinds like tariffs, along with its expanding partnerships and AI initiatives. Bullish sentiment is fueled by raised price targets and the anticipation of continued growth, though some caution against overvaluation.

Bakkt Holdings, Inc. engages in the intersection of cryptoassets, loyalty and rewards, and payments. It also provides a platform to expand payment offerings, create new revenue streams, and increase customer loyalty. The company was founded in 2018 and is headquartered in Alpharetta, GA.

Bakkt Holdings Inc - Ordinary Shares - Class A

Bakkt Holdings Inc

Bakkt Holdings is trending due to renewed interest following news of a new board appointment, sparking discussions about the company's potential growth strategy within the digital asset space. The community is actively speculating about the impact of new leadership and potential partnerships, especially regarding expansion into foreign markets and web3 technologies. Bullish sentiment is building around the possibility of a short squeeze and the company's strengthened financial position after debt reduction.

Rezolve AI Plc operates in the mobile commerce industry with its cutting-edge engagement platform powered by artificial intelligence and machine learning. It develops AI-based mobile commerce and engagement solutions, simplifying the purchasing process by providing relevant information and facilitating seamless transactions with a single tap. The company enables retailers, brands, and manufacturers to create dynamic connections with consumers across mobile and desktop devices. Rezolve Ai was founded in 2016 and is headquartered in London, the United Kingdom.

Rezolve AI PLC .

Rezolve AI Limited

Rezolve AI ($RZLV) is trending amidst a short report from Fuzzy Panda Research, alleging inflated ARR and questionable partnerships, which the company has refuted. The community is fiercely debating the report's validity, with some viewing it as a buying opportunity ahead of earnings and others expressing concern. Bulls emphasize institutional investment and potential for high growth in the AI-powered commerce sector, while bears point to past financial performance and management's track record.

Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases. The firm also conducts research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19). The company was founded by Peter O. Kliem Martin Karplus, James Hogle, Gerard Wagner, Peter M. Howley, and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.

Enanta Pharmaceuticals Inc

Enanta Pharmaceuticals (ENTA) is trending due to mixed Phase 2b study results for its RSV treatment, zelicapavir, causing investor debate and a stock sell-off. While the primary endpoint was missed, secondary endpoints were met, fueling discussions about the drug's potential and Phase 3 progression, particularly regarding FDA priorities. Community talking points include potential short squeezes given the high short interest and oversold RSI.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AMN Healthcare Services (AMN) Tops Q2 Earnings and Revenue Estimates

AMN Healthcare (AMN) delivered earnings and revenue surprises of +76.47% and +0.87%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Healthcare technology firm Aclarion Inc.'s (ACON) stock surged nearly 127% on Monday, marking its best single-day gain since going public in 2022.&nbsp;The surge followed news that Aclarion has entered into a commercial agreement with Scripps Health, bringing its Nociscan technology — a noninvasive tool that helps physicians personalize treatment for chronic lower back pain — to Scripps' network of doctors in San Diego, California.Aclarion says the deal will allow Scripps physicians to better differentiate between painful and non-painful lumbar discs using magnetic resonance spectroscopy and advanced signal processing.&nbsp;While the partnership's financial terms were not disclosed, the news generated widespread enthusiasm among retail traders, driving a dramatic surge in trading activity and online discussions.Investor chatter on Stocktwits turned sharply bullish in response to the announcement. The company's follower count on the platform jumped nearly 20%, while message volume surged by over 6,000% by the end of Monday's session.A Stocktwits poll found that 41% of more than 1,100 retail traders view the partnership as a "game-changer," while 32% describe it as "short-term hype, long-term unknown." The remaining see it as a "liquidity event" or too early to make a definitive judgment.Retail traders debated the deal's broader implications, with one suggesting that it could make Aclarion a potential acquisition target for major medical technology firms.&nbsp;One user speculated that a buyout by a company like Medtronic could send the stock significantly higher, while another dismissed concerns about potential dilution, predicting a run to $10–$20.<stembedurl>https://stocktwits.com/TraderMitsos/message/606583790</stembedurl><stembedurl>https://stocktwits.com/Hotoilguy/message/606598370</stembedurl>Aclarion, which has a market capitalization of just $7.7 million, remains an early-stage company that has yet to generate revenue.&nbsp;Short interest on the stock has jumped from 11.8% at the start of 2025 to 24.2% by the end of last week, according to Koyfin.Following Monday's rally, <a href="https://stocktwits.com/symbol/ACON">Aclarion shares</a> are now up over 5% year-to-date. According to Koyfin data, only two analysts currently cover Aclarion, with one rating it a 'Buy' and the other a 'Hold.'The stock was seeing heavy profit-taking in Monday's after-hours trading, falling over 14%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Is Aclarion's Tie-Up With Scripps Health A Lasting Catalyst? Most Retail Traders Think It's A 'Game-Changer'

The company's follower count on Stocktwits jumped nearly 20%, while message volume surged by over 6,000% by the end of Monday's session.

Equity

The company's follower count on Stocktwits jumped nearly 20%, while message volume surged by over 6,000% by the end of Monday's session.


Aclarion Inc. shares surged 94% on Thursday afternoon in heavy trading after the healthcare technology company executed a 1-for-335 reverse stock split.&nbsp;The move reduced its outstanding common shares from approximately 169.4 million pre-split to around 500,000 post-split.The reverse split propelled Aclarion to the top of Stocktwits’ trending tickers, with its retail following jumping 59% from Wednesday’s close.&nbsp;Bullish traders speculated the stock could climb another 45% from current levels, while some anticipated a near-tripling.<stembedurl>https://stocktwits.com/GreenReaperx/message/602177528</stembedurl><stembedurl>https://stocktwits.com/SCNC/message/602177417</stembedurl>Aclarion specializes in Magnetic Resonance Spectroscopy (MRS) and augmented intelligence algorithms to help physicians pinpoint sources of chronic low back pain through its SaaS platform, Nociscan.&nbsp;Earlier this month, the stock received a boost after the company announced it had terminated an agreement with Ascendiant Capital for a $10 million at-the-market share offering.&nbsp;According to a regulatory filing, Aclarion raised about $300,000 in gross proceeds before canceling the deal, which was initiated in September 2024.Despite losing&nbsp;over 71% of its value over the past three months, Aclarion’s retail following on Stocktwits has surged 50%, with message volume soaring over 6,000%.Aclarion’s stock last had a short interest of 17.4%, according to Koyfin data.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a stock chart | Image source: Maria Korneeva on Getty Images

Aclarion’s Retail Following Jumps 60% After Reverse Stock Split As Micro-Cap Health Tech Shares Nearly Double

Earlier this month, the stock received a boost after the company announced it had terminated an agreement with Ascendiant Capital for a $10 million at-the-market share offering.

Analysts Offer Insights on Healthcare Companies: Aclarion, Inc. (ACON), Edwards Lifesciences (EW) and Sanofi (OtherSNYNF)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Aclarion, Inc. (ACON Research Report), Edwards Lifesciences (EW...

Aclarion, Inc. (NASDAQ:ACON) Sees Large Increase in Short Interest

Aclarion, Inc. (NASDAQ:ACON  Get Free Report) saw a significant growth in short interest during the month of February. As of February 29th, there was short interest totalling 159,100 shares...

Aclarion announces publication of peer-reviewed data in journal on lumbar discs

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Aclarion Announces Publication of Compelling Peer-Reviewed Data in International Journal of Spine Surgery Supporting Nociscan as a Gold Standard for Noninvasive Identification of Painful Lumbar Discs

Confirms predictive value of Nociscan for identifying painful discs. Nociscan demonstrated a sensitivity of 100% and a specificity of 80% compared to provocative discography (PD), suggesting...

Aclarion Announces Closing of $3.0 Million Public Offering

BROOMFIELD, CO, Feb. 27, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire - Aclarion, Inc. ( Aclarion or the Company ) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging...

Aclarion Announces Pricing of $3.0 Million Public Offering

BROOMFIELD, CO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc. ( Aclarion or the Company ) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging...

Aclarion Announces Successful Financings; Plans to Launch CLARITY Trial and Provides Update on Next Steps of Alphatec Strategic Partnership

Company is initiating its pivotal multicenter, prospective, randomized CLARITY trial to build on clinical evidence demonstrating superior surgical outcomes when Nociscan is utilized in surgical...

Aclarion, Inc. is a healthcare technology company, which engages in the provision of Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. It utilizes Artificial Intelligence to assist in quality control processes that flag spectroscopy data indicative of a poor MRS study. It offers NOCISCAN Suite, a revolutionary software suite that works with existing high field Magnetic Resonance systems and Magnetic Resonance Spectroscopy pulse sequence packages using an optimized protocol to conduct MRS exams of lumbar discs. The company was founded by James C. Peacock, David S. Bradford, and Jeffrey Lotz in 2008 and is headquartered in Broomfield, CO.

Aclarion Inc

Will the U.S. government shut down in 2025? 
 
*Powered by Polymarket

ACON
Aclarion Inc

Feed

News

Sentiment

Fundamentals

Info

Latest ACON News

ACON Aclarion Inc